Melinta Therapeutics, Inc. (MLNT) Receives Consensus Rating of “Hold” from Analysts

Melinta Therapeutics, Inc. (NASDAQ:MLNT) has received a consensus rating of “Hold” from the ten brokerages that are presently covering the company, MarketBeat reports. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $3.72.

MLNT has been the subject of several analyst reports. Zacks Investment Research upgraded Melinta Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 17th. Jefferies Group restated a “neutral” rating on shares of Melinta Therapeutics in a research report on Thursday, October 26th. Robert W. Baird upgraded Melinta Therapeutics from an “underperform” rating to a “neutral” rating and set a $2.00 target price for the company in a research report on Wednesday, November 1st. ValuEngine upgraded Melinta Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 8th. Finally, Ladenburg Thalmann Financial Services upgraded Melinta Therapeutics from a “neutral” rating to a “buy” rating in a research report on Thursday, November 30th.

In related news, Director Vatera Healthcare Partners Llc bought 5,777,778 shares of the business’s stock in a transaction that occurred on Friday, January 5th. The stock was acquired at an average price of $13.50 per share, for a total transaction of $78,000,003.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. 31.50% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the business. Teton Advisors Inc. bought a new position in Melinta Therapeutics in the 4th quarter valued at $237,000. Alambic Investment Management L.P. bought a new position in Melinta Therapeutics in the 4th quarter valued at $207,000. Franklin Street Advisors Inc. NC bought a new position in Melinta Therapeutics in the 4th quarter valued at $204,000. California Public Employees Retirement System bought a new position in Melinta Therapeutics in the 4th quarter valued at $246,000. Finally, Schwab Charles Investment Management Inc. bought a new position in Melinta Therapeutics in the 4th quarter valued at $753,000.

Shares of Melinta Therapeutics (MLNT) opened at $12.15 on Tuesday. The company has a current ratio of 11.49, a quick ratio of 11.49 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $380.60, a P/E ratio of -1.66 and a beta of 1.01. Melinta Therapeutics has a fifty-two week low of $10.25 and a fifty-two week high of $24.25.

ILLEGAL ACTIVITY WARNING: “Melinta Therapeutics, Inc. (MLNT) Receives Consensus Rating of “Hold” from Analysts” was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2018/02/13/melinta-therapeutics-inc-mlnt-receives-consensus-rating-of-hold-from-analysts.html.

About Melinta Therapeutics

Melinta Therapeutics, Inc develops and commercializes novel antibiotics designed to provide therapeutic solutions. The Company’s lead product is Baxdela, an antibiotic approved by the United States food and drug administration (FDA) for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI).

Analyst Recommendations for Melinta Therapeutics (NASDAQ:MLNT)

Receive News & Ratings for Melinta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Melinta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply